{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:32:58Z","timestamp":1790695978912,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":1623,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"crossref","award":["KKL631"],"award-info":[{"award-number":["KKL631"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C15759\/A12328"],"award-info":[{"award-number":["C15759\/A12328"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1093\/annonc\/mdv110","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T10:22:27Z","timestamp":1424946147000},"page":"1180-1187","source":"Crossref","is-referenced-by-count":15,"title":["A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia"],"prefix":"10.1016","volume":"26","author":[{"given":"K.","family":"Korfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Furney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.C.P.","family":"Somervaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv110_bb0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv110_bb0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv110_bb0020","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdv110_bb0025","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv110_bb0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdv110_bb0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv110_bb0040","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv110_bb0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv110_bb0050","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv110_bb0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdv110_bb0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv110_bb0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv110_bb0070","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv110_bb0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdv110_bb0080","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv110_bb0085","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","article-title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","volume":"98","author":"Clark","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv110_bb0090","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","article-title":"Autocrine TNF-alpha production supports CML stem and progenitor cell survival and enhances their proliferation","volume":"122","author":"Gallipoli","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv110_bb0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv110_bb0100","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.1633833100","article-title":"Expression of BCR\/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias","volume":"100","author":"Jaiswal","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdv110_bb0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1093\/annonc\/mdv110_bb0110","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv110_bb0115","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/leu.2013.151","article-title":"Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target","volume":"27","author":"Harb","year":"2013","journal-title":"Leukemia"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/6\/1180\/16699845\/mdv110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:49:03Z","timestamp":1624520943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0923753419318010"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv110","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}